Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Receivables (2016 - 2024)

Historic Change in Receivables for vTv Therapeutics (VTVT) over the last 10 years, with Q4 2024 value amounting to -$180000.0.

  • vTv Therapeutics' Change in Receivables fell 27647.06% to -$180000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$40000.0, marking a year-over-year increase of 4366.2%. This contributed to the annual value of -$40000.0 for FY2024, which is 4366.2% up from last year.
  • According to the latest figures from Q4 2024, vTv Therapeutics' Change in Receivables is -$180000.0, which was down 27647.06% from -$64000.0 recorded in Q3 2024.
  • In the past 5 years, vTv Therapeutics' Change in Receivables registered a high of $928000.0 during Q3 2021, and its lowest value of -$871000.0 during Q4 2021.
  • For the 5-year period, vTv Therapeutics' Change in Receivables averaged around $4133.3, with its median value being -$2000.0 (2021).
  • The largest annual percentage gain for vTv Therapeutics' Change in Receivables in the last 5 years was 652857.14% (2021), contrasted with its biggest fall of 70486.11% (2021).
  • vTv Therapeutics' Change in Receivables (Quarter) stood at $144000.0 in 2020, then plummeted by 704.86% to -$871000.0 in 2021, then surged by 113.32% to $116000.0 in 2022, then decreased by 12.07% to $102000.0 in 2023, then tumbled by 276.47% to -$180000.0 in 2024.
  • Its Change in Receivables was -$180000.0 in Q4 2024, compared to -$64000.0 in Q3 2024 and -$675000.0 in Q2 2024.